Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Bedossa

Showing results (161-170 of 267) with videos related to

Pageof 27
Sort By:
Chest|October 8, 2018
Evidence for an Association Between Intrahepatic Vascular Changes and the Development of Hepatopulmonary SyndromeClément Lejealle, Valérie Paradis, Onorina Bruno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2012
Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patientsDaniela Speisky, Aurélie Duces, Ivan Bièche, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2021
Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric SurgeryPierre Bel Lassen, Nicole Nori, Pierre Bedossa, et al.
European Journal of Immunology|November 23, 2011
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patientsVivien Béziat, Olav Dalgard, Tarik Asselah, et al.
Journal of Hepatology|October 11, 2012
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type IJulien Calderaro, Philippe Labrune, Guillaume Morcrette, et al.
Scientific Reports|June 11, 2020
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver DiseaseDivya P Kumar, Rebecca Caffrey, Jonathon Marioneaux, et al.
Diagnostics (Basel, Switzerland)|September 3, 2020
An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical TrialsWei-Qiang Leow, Pierre Bedossa, Feng Liu, et al.
Gastroenterology|January 29, 2019
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver DiseasePeter J Eddowes, Magali Sasso, Michael Allison, et al.
Plos One|March 21, 2012
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient dataThierry Poynard, Guillaume Lassailly, Emmanuel Diaz, et al.
Genome Biology|January 23, 2008
Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesityCorneliu Henegar, Joan Tordjman, Vincent Achard, et al.
Pageof 27

Showing results (161-170 of 267) with videos related to

Sort By:
Pageof 27
Chest|October 8, 2018
Evidence for an Association Between Intrahepatic Vascular Changes and the Development of Hepatopulmonary SyndromeClément Lejealle, Valérie Paradis, Onorina Bruno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2012
Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patientsDaniela Speisky, Aurélie Duces, Ivan Bièche, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2021
Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric SurgeryPierre Bel Lassen, Nicole Nori, Pierre Bedossa, et al.
European Journal of Immunology|November 23, 2011
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patientsVivien Béziat, Olav Dalgard, Tarik Asselah, et al.
Journal of Hepatology|October 11, 2012
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type IJulien Calderaro, Philippe Labrune, Guillaume Morcrette, et al.
Scientific Reports|June 11, 2020
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver DiseaseDivya P Kumar, Rebecca Caffrey, Jonathon Marioneaux, et al.
Diagnostics (Basel, Switzerland)|September 3, 2020
An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical TrialsWei-Qiang Leow, Pierre Bedossa, Feng Liu, et al.
Gastroenterology|January 29, 2019
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver DiseasePeter J Eddowes, Magali Sasso, Michael Allison, et al.
Plos One|March 21, 2012
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient dataThierry Poynard, Guillaume Lassailly, Emmanuel Diaz, et al.
Genome Biology|January 23, 2008
Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesityCorneliu Henegar, Joan Tordjman, Vincent Achard, et al.
Pageof 27